Results by Type
News Results 1-10 of 26
Sponsored Links
Get Rid of Ringworm Quick
Safe, Fast, & Effective Treatment Guaranteed, Pharmaceutical-Strength
Fungal Infection Relief
Fast relief for athlete foot, jock itch and ringworm. 100% Guaranteed.
FDA Approves Use of Bristol-Myers Squibb Company's REYATAZ(R) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients
News | www.biospace.com | Oct 2, 2008
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company announced today that the U.S. Food & Drug Administration approved the use of REYATAZ (atazanavir sulfate) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in previously untreated (treatment-naive) HIV-1
http://www.biospace.com/news_story.aspx?StoryID=111678&full=1
U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients (Business Wire)
News | biz.yahoo.com | Oct 1, 2008
U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients. - PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) announced today that the
A Tale of Three Pharmaceuticals: Abbott Labs, Pfizer and Eli Lilly & Co. (at Seeking Alpha)
News | seekingalpha.com | Sep 23, 2008
Investors have long enjoyed a love-hate relationship with pharmaceutical stocks. This sector is unique in that their products are effectively scheduled for obsolescence via expiring patents.
Catching the blood cell bus gives fatal yeast infection a clean getaway
News | www.news-medical.net | Sep 9, 2008
Yeast fungus cells that kill thousands of AIDS patients every year escape detection by our bodies' defences by hiding inside our own defence cells, and hitch a ride through our systems before attacking and spreading, scientists heard today (Tuesday 9 September 2008) at the Society for General
Cryptococcus Yeast Eludes Detection by Using Macrophages to Travel through the Body
News | www.genengnews.com | Sep 9, 2008
Cryptococcus Yeast Eludes Detection by Using Macrophages to Travel through the Body. Genetic Engineering & Biotechnology News - Biotechnology from Bench to Business. The Leading Publication in Biotechnology. Genetic Engineering News is the most widely read bioindustry publication worldwide and has
FDA orders stronger warnings for 4 arthritis drugs (AP)
News | us.rd.yahoo.com | Sep 4, 2008
FDA orders stronger warnings for 4 arthritis drugs. - WASHINGTON (AP) -- The Food and Drug Administration ordered stronger warnings Thursday on four medications widely used to treat rheumatoid arthritis and other serious illnesses, saying they can raise the risk of possibly fatal fungal infections.
BioDelivery Sciences receives FDA's complete response letter for pain drug
News | www.pharmaceutical-business-review.com | Sep 1, 2008
BioDelivery Sciences International, a specialty pharmaceutical company, has received a complete response letter from the FDA regarding the companys new drug application for Bema Fentanyl, which will be marketed in the US as Onsolis.
Abbott Study Shows Investigational Heat-Stable Norvir® Tablet Provides Similar Drug Levels to Current Norvir Capsule
Press Release | www.abbott.com | Aug 7, 2008
Abbott Study Shows Investigational Heat-Stable Norvir® Tablet Provides Similar Drug Levels to Current Norvir Capsule
http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0645.htm?referrer=RSS
New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
Press Release | www.prnewswire.com | Jan 31, 2008
Two landmark clinical studies demonstrating the efficacy of NOXAFIL prophylaxis were published in The New England Journal of Medicine in January 2007.
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/01-31-2008/0004747104&EDATE=
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans
News | www.jci.org | Jan 1, 1970
Atherosclerosis remains a major cause of death in the developed world despite the success of therapies that lower cholesterol and BP. The intermediate-conductance calcium-activated potassium channel KCa3.1 is expressed in multiple cell types implicated in atherogenesis, and pharmacological blockade
Sponsored Links
Fungus and Yeast Relief
Fungal and Candida Infection remedy Discover the Natural Cure Today!
Or copy the embed script code below and paste it on your website:
Embed code:
>
